AUTHOR=Guo Ruiting , Lu Wenyi , Zhang Yi , Cao Xinping , Jin Xin , Zhao Mingfeng 

TITLE=Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.839097

DOI=10.3389/fimmu.2022.839097

ISSN=1664-3224

ABSTRACT=<p>With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For the past few years, significant progress has been made in various BCMA-targeted immunotherapies for treating patients with RRMM, including anti-BCMA mAbs, antibody-drug conjugates, bispecific T-cell engagers, and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell. The 63rd annual meeting of the American Society of Hematology updated some information about the application of BCMA in MM. This review summarizes part of the related points presented at this conference.</p>